• Price (USD)76.29
  • Today's Change0.00 / 0.00%
  • Shares traded17.55k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 26 2021 18:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s products include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery and acute therapies. Its renal care offering includes peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. Its medication delivery offerings include intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices. Its pharmaceuticals offerings include premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. Its clinical nutrition offerings include parenteral nutrition (PN) therapies and related products. Its advanced surgery offerings include biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. It also offers polysaccharide hemostatic system (PerClot) products.

  • Revenue in USD (TTM)12.45bn
  • Net income in USD1.21bn
  • Incorporated1931
  • Employees50.00k
  • Location
    Baxter International Inc1 Baxter PkwyDEERFIELD 60015-4625United StatesUSA
  • Phone+1 (847) 948-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.baxter.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BAX:NYQ since
Hill-Rom Holdings IncAnnounced02 Sep 202102 Sep 2021Announced-1.69%10.42bn
Omnicell IncRumoured08 Dec 202008 Dec 2020Rumoured-1.90%--
Data delayed at least 15 minutes, as of Nov 26 2021 18:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.